A halogen-containing compound as shown in a formula I can be used as a ligand for an ethylene oligomerization catalyst composition. The ethylene oligomerization catalyst composition containing the halogen-containing compound can be used to catalyze ethylene oligomerization, trimerization and tetramerization reactions. As a ligand of a catalyst for ethylene oligomerization, a fluoropolymer can effectively improve the catalytic performance of a catalyst system, and particularly exhibits improved activity and selectivity in an ethylene oligomerization reaction. ##STR00001##

Method for the production of tetrakis(trihydrocarbylphosphane)palladium(0) in organic solvent, whereby 50 to 100% by weight of the organic solvent consist of at least one polar-aprotic solvent, characterised in that a) at least one palladium compound selected from the group consisting of palladium(II) compounds and palladium(IV) compounds that are soluble in the organic solvent is reacted with b) at least one base, selected from the group consisting of alkali metal hydroxides, alkali metal carbonates, alkali metal hydrogen carbonates, alkali metal-C.sub.1-C.sub.4-alcoholates, ammonium carbonate, ammonium hydrogen carbonate, alkaline earth metal hydroxides, alkaline earth metal carbonates, alkaline earth metal hydrogen carbonates, alkaline earth metal-C.sub.1-C.sub.4-alcoholates, and alkylamines with a total of 2 to 12 carbon atoms; c) at least one trihydrocarbylphosphane; and d) at least one organic reducing agent that is different from the remaining components that are used in the method.

A halogen-containing compound as shown in a formula I can be used as a ligand for an ethylene oligomerization catalyst composition. The ethylene oligomerization catalyst composition containing the halogen-containing compound can be used to catalyze ethylene oligomerization, trimerization, and tetramerization reactions. As a ligand of a catalyst for ethylene oligomerization, a fluoropolymer can effectively improve the catalytic performance of a catalyst system, and particularly exhibits improved activity and selectivity in an ethylene oligomerization reaction.

##STR00001##

Provided are a novel catalyst component for producing an α-olefin (co)polymer, and a production method using the same. A metal complex is obtainable by contacting a compound represented by the general formula [I] or [II] with a transition metal compound containing a transition metal belonging to 9th to 11th group: ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 represent (i) hydrogen, (ii) a halogen, (iii) a linear alkyl or the like, or (iv) OR.sup.9 or the like; R.sup.5 and R.sup.6 represent a linear alkyl group or the like; any one of R.sup.1-R.sup.6 may have a heteroatom or a heteroatom containing group; E.sup.1 represents phosphorus, arsenic or antimony; X.sup.1 represents oxygen or sulfur; Z represents hydrogen or a leaving group.

The phosphine transition metal complex of the present invention is represented by formula (1). ##STR00001##
Preferably, R.sup.1 and R.sup.6 are identical groups, R.sup.2 and R.sup.7 are identical groups, R.sup.3 and R.sup.8 are identical groups, R.sup.4 and R.sup.9 are identical groups, R.sup.5 and R.sup.10 are identical groups, and n and y are identical numbers. The phosphine transition metal complex is suitably obtained by reacting a phosphine derivative represented by formula (2) and a phosphine derivative represented by formula (3) with a salt of a transition metal of gold, copper or silver. ##STR00002##
See the description for the meanings of the symbols in each formula.

Mixed ligand phosphinogold(I) complexes as anticancer agents. The gold(I) ion of the complexes is coordinated to a phosphine and a dithiocarbamate or halogen ligand. Also described are a pharmaceutical composition incorporating the phosphinogold(I) complex, a method of synthesizing the phosphinogold(I) complex, and a method of treating cancer. The phosphinogold(I) complexes exhibit potent cytotoxicity against lung, cervical, and liver cancer cells.

The present invention relates to gold (I)-phosphine 1,2,3-triazole compounds, and their use in a human or animal medicine. The present invention also relates to using such compounds for the prevention and/or treatment of an infection, i.e. inhibitors of growth of Gram-positive and/or Gram-negative bacteria. On another aspect the invention relates to the synthesis of the gold (I)-phosphine compounds of the invention and to their synthesis intermediates. The present invention finds applications in the medical, veterinary and/or chemical fields.

##STR00001##

Platinum complexes having benzyl-based diphosphine ligands for the catalysis of the alkoxycarbonylation of ethylenically unsaturated compounds.

The present invention relates to tetra-nuclear neutral copper (I) complexes that have a cubane-like structure, wherein said complexes further comprise diarylphosphine ligands which are bonded via phosphorus atoms. Furthermore, the present invention refers to methods for generating such copper (I) complex and to uses thereof. The present invention further relates to cubane-like conjugates that comprise moiety of the copper (I) complexes of the invention. Formula (A), each L is independently from each other an optionally substituted diary lphosphine residue of Formula (A1): PHSr.sub.2 (A1).

##STR00001##

The phosphine transition metal complex of the present invention is represented by formula (1).

##STR00001##

Preferably, R.sup.1 and R.sup.6 are identical groups, R.sup.2 and R.sup.7 are identical groups, R.sup.3 and R.sup.8 are identical groups, R.sup.4 and R.sup.9 are identical groups, R.sup.5 and R.sup.10 are identical groups, and n and y are identical numbers. The phosphine transition metal complex is suitably obtained by reacting a phosphine derivative represented by formula (2) and a phosphine derivative represented by formula (3) with a salt of a transition metal of gold, copper or silver.

##STR00002##

See the description for the meanings of the symbols in each formula.